Managers / Q3 2019 · view latest →
Aquilo Capital Management, LLC
CIK 0001591986 · ONE LETTERMAN DRIVE, SUITE D4900, BUILDING D, SAN FRANCISCO, CA, 94129 · 415-635-0140
Summary
Aquilo Capital Management, LLC reported $142M in U.S.-listed holdings across 11 positions for Q3 2019.
Its largest position, Merus N V, represents 13.0% of the portfolio.
Compared with Q2 2019, the fund opened 0 new positions and exited 3.
Portfolio Metrics
Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded, with multiple share classes and repeated sub-manager rows for the same issuer combined into one position — the same rule the holdings table uses by default. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.
Reported Value by Quarter
Portfolio Composition
- Common Stock · 44.5% · $63M
- ETP · 26.8% · $38M
- Other · 16.4% · $23M
- ADR · 12.3% · $17M
Quarter-over-Quarter Changes full breakdown →
vs Q2 2019 (amended baseline)
| Issuer | Move | Share Δ | Shares now | Value Δ | Value now |
|---|---|---|---|---|---|
| QUREUNIQURE NV | ADDED | +426.6K | 791.2K | +$3M | $31M |
| PIERIS PHARMACEUTICALS INC | ADDED | +1.51M | 2.96M | +$3M | $10M |
| IBBISHARES TR | SOLD OUT | −1.00M | 0 | −$109M | $0 |
| ARWRARROWHEAD PHARMACEUTICALS IN | SOLD OUT | −557.5K | 0 | −$15M | $0 |
| SYNLOGIC INC | SOLD OUT | −1.04M | 0 | −$10M | $0 |
| FATEFATE THERAPEUTICS INC | TRIMMED | −529.8K | 72.3K | −$11M | $1M |
| MERUS N V | TRIMMED | −352.8K | 1.04M | −$2M | $19M |
| GALAPAGOS NV | ADDED | +10.0K | 56.8K | +$3M | $9M |
Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.
Holdings — Q3 2019
| # | Issuer | Class | % Portfolio | Value ↓ | Shares |
|---|---|---|---|---|---|
| 1 | MERUS N V | COM | 13.04% | $19M | 1.04M |
| 2 | QUREUNIQURE NVhistory → | SHS | 10.84% | $15M | 391.2K |
| 3 | SPROSPERO THERAPEUTICS INChistory → | COM | 8.62% | $12M | 1.15M |
| 4 | PIERIS PHARMACEUTICALS INC | COM | 7.10% | $10M | 2.96M |
| 5 | BCYCBICYCLE THERAPEUTICS PLChistory → | SPONSORED ADS | 6.15% | $9M | 767.0K |
| 6 | GALAPAGOS NV | SPON ADR | 6.11% | $9M | 56.8K |
| 7 | XENEXENON PHARMACEUTICALS INChistory → | COM | 6.04% | $9M | 951.5K |
| 8 | PROQR THRAPEUTICS N V | SHS EURO | 3.37% | $5M | 831.7K |
| 9 | FATEFATE THERAPEUTICS INC | COM | 0.79% | $1M | 72.3K |
Filing History
| Quarter | Reported Value | Positions | Filed | Type | Links |
|---|---|---|---|---|---|
| Q3 2025 | $0 | 1 | Nov 12, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q2 2025 | $0 | 1 | Aug 6, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q1 2025 | $56M | 13 | May 15, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q4 2024 | $66M | 15 | Feb 14, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q3 2024 | $132M | 14 | Nov 14, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q2 2024 | $104M | 13 | Aug 14, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q1 2024 | $133M | 10 | May 15, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q4 2023 | $160M | 10 | Feb 14, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q3 2023 | $110M | 12 | Nov 14, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q2 2023 | $180M | 13 | Aug 14, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q1 2023 | $241M | 12 | May 15, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q4 2022 | $266M | 13 | Feb 14, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q3 2022 | $277M | 15 | Nov 14, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q2 2022 | $293M | 13 | Aug 15, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q1 2022 | $680M | 14 | May 16, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q4 2021 | $882M | 14 | Feb 14, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q3 2021 | $551M | 14 | Nov 15, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q2 2021 | $385M | 15 | Aug 16, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q1 2021 | $553M | 17 | May 17, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q4 2020 | $481M | 17 | Feb 16, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q3 2020 | $945M | 17 | Nov 16, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q2 2020 | $496M | 14 | Aug 14, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q1 2020 | $257M | 14 | May 15, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q4 2019 | $266M | 12 | Feb 14, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q3 2019 | $142M | 11 | Nov 14, 2019 | 13F-HR | changes · EDGAR ↗ |
| Q2 2019 | $288M | 13 | Aug 14, 2019 | 13F-HR | changes · EDGAR ↗ |
| Q1 2019 | $226M | 14 | May 15, 2019 | 13F-HR | changes · EDGAR ↗ |
13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.